The Financial Post reports in its Wednesday edition there is no time like the present when it comes to buying marijuana stocks, says Neal Gilmer, analyst at Clarus Securities. The Post's David Pett writes, however, it will not be an easy ride for investors. "We believe that the near term is likely to have material volatility as all of these companies are essentially start-ups in an infant industry," he said in a note. "However, we believe that longer-term, early investors stand to be well rewarded for taking on the risk." Mr. Gilmer is the latest analyst to initiate coverage on Bedrocan Cannabis (65 cents). He has a speculative buy and $1.50 price target on the stock. Bedrocan still needs to receive a licence to grow medical marijuana from Health Canada, but once that is done it will be a "significant de-risking event that will be a key catalyst." Mr. Gilmer prefers the Canadian marijuana market to that in the United States because of Canada's low-cost "Amazon.com-style" distribution model. "With a direct-to-patient shipping model, producers in Canada can capture what would be considered to be both wholesale and retail margins without incurring the costs for real estate for a retail storefront," he said.